ALQGC — Quantum Genomics SA Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Quantum Genomics Completes Patient Recruitment In Phase IIB Hypertension Study
Brief: Quantum Genomics Announces Trial Design For Quorum, Its Phase IIB Study In Heart Failure
Brief: Quantum Genomics Presents Its 3-Year Strategic Plan
Brief: Quantum Genomics Announces Separation Of Functions Of Chairman And CEO
Brief: Quantum Genomics FY Net Loss Widens To 9.4 Million Euros
Brief: Quantum Genomics Launches Equity Line Financing With Kepler Cheuvreux
Brief: Quantum Genomics recruits first patients in NEW-HOPE hypertension study in the US
Brief: Quantum Genomics H1 operating loss widens to 4.5 million euros
Brief: Quantum Genomics receives FDA clearance of IND application for QGC001
Brief: Quantum Genomics raises 8.2 million euros in Europe and US
Brief: Quantum Genomics begins trading in the US
Brief: Quantum Genomics announces design of its next phase II trial in arterial hypertension
Brief: Quantum Genomics announces positive results of phase IIa study on QGC001
Brief: Quantum Genomics appoints Bruno Besse as Chief Medical Officer
Brief: Quantum Genomics FY operating loss widens at 6.2 million euros
Brief: Quantum Genomics announces data from new preclinical studies with QGC001
Brief: Quantum Genomics granted key European patent for QGC011 combination therapy program
Brief: Quantum Genomics H1 net loss widens to 2.8 million euros
Brief: Quantum Genomics announces positive results on phase II of QGC001 arterial hypertension